Branched-Chain Amino Acids Exacerbate Obesity-Related Hepatic Glucose and Lipid Metabolic Disorders via Attenuating Akt2 Signaling
- 17 March 2020
- journal article
- research article
- Published by American Diabetes Association in Diabetes
- Vol. 69 (6), 1164-1177
- https://doi.org/10.2337/db19-0920
Abstract
Branched chain amino acids (BCAAs) are associated with the progression of obesity-related metabolic disorders, including type 2 diabetes and nonalcoholic fatty liver disease. However, whether BCAAs disrupt the homeostasis of hepatic glucose and lipid metabolism remains unknown. In this study, we observed that BCAAs supplementation significantly reduced high-fat (HF) diet–induced hepatic lipid accumulation while increasing the plasma lipid levels and promoting muscular and renal lipid accumulation. Further studies demonstrated that BCAAs supplementation significantly increased hepatic gluconeogenesis and suppressed hepatic lipogenesis in HF diet-induced obese (DIO) mice. These phenotypes resulted from severe attenuation of Akt2 signaling via mTORC1- and mTORC2-dependent pathways. BCAAs/branched-chain α-keto acids (BCKAs) chronically suppressed Akt2 activation through mTORC1 and mTORC2 signaling and promoted Akt2 ubiquitin-proteasome–dependent degradation through the mTORC2 pathway. Moreover, the E3 ligase Mul1 played an essential role in BCAAs/BCKAs-mTORC2-induced Akt2 ubiquitin-dependent degradation. We also demonstrated that BCAAs inhibited hepatic lipogenesis by blocking Akt2/SREBP1/INSIG2a signaling and increased hepatic glycogenesis by regulating Akt2/Foxo1 signaling. Collectively, these data demonstrate that in DIO mice, BCAAs supplementation resulted in serious hepatic metabolic disorder and severe liver insulin resistance: insulin failed to not only suppress gluconeogenesis but also activate lipogenesis. Intervening BCAA metabolism is a potential therapeutic target for severe insulin-resistant disease.Keywords
This publication has 44 references indexed in Scilit:
- Akt is negatively regulated by the MULAN E3 ligaseCell Research, 2012
- Akt Stimulates Hepatic SREBP1c and Lipogenesis through Parallel mTORC1-Dependent and Independent PathwaysCell Metabolism, 2011
- Akt2 Is Required for Hepatic Lipid Accumulation in Models of Insulin ResistanceCell Metabolism, 2009
- The E3 Ligase TRAF6 Regulates Akt Ubiquitination and ActivationScience, 2009
- A Branched-Chain Amino Acid-Related Metabolic Signature that Differentiates Obese and Lean Humans and Contributes to Insulin ResistanceCell Metabolism, 2009
- Negative Regulation of AKT Activation by BRCA1Cancer Research, 2008
- SREBP Activity Is Regulated by mTORC1 and Contributes to Akt-Dependent Cell GrowthCell Metabolism, 2008
- Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signallingThe EMBO Journal, 2008
- Akt and CHIP coregulate tau degradation through coordinated interactionsProceedings of the National Academy of Sciences of the United States of America, 2008
- Selective versus Total Insulin Resistance: A Pathogenic ParadoxCell Metabolism, 2008